(+)-(1S,2R)-2-Phenylcyclohexanamine | 37982-23-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (+)-(1S,2R)-2-Phenylcyclohexanamine
• 英文别名: (1S,2R)-2-phenylcyclohexanamine；trans-2-phenylcyclohexanamine；1e-Phenyl-2e-amino-cyclohexan；trans-2-Phenyl-cyclohexylamin；2e-Phenylcyclohexylamin (e)；(1S,2R)-2-phenylcyclohexan-1-amine
• CAS: 37982-23-3
• 化学式: C₁₂H₁₇N
• 分子量: 175.274
• InChiKey: KLJIPLWGNJQJRM-NEPJUHHUSA-N

物化性质

• 熔点：
  41.5-42 °C
• 沸点：
  278.6±29.0 °C(Predicted)
• 密度：
  0.983±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (+)-(1S,2R)-2-Phenylcyclohexanamine 在 rose bengal 、 氧气 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 生成 4-苯甲酰基丁酸
  参考文献：
  名称：

  可见光促进伯胺的无金属有氧氧化为酸和内酯

  摘要：

  通过可见光光催化双碳-碳键断裂和多碳-氢键氧化，独特地进行了伯胺的无金属好氧氧化。通过使用具有18 W CFL的二恶烷，可以控制伯胺的好氧氧化，以提供酸；通过使用具有8 W绿色LED的DMF，可以分别控制内酯的内酯。在控制实验的基础上，提出了一个合理的机制。该观察结果为脂肪族伯胺的好氧氧化中的碎片化提供了直接证据。

  DOI：

  10.1002/chem.201604440
• 作为产物：
  描述：

  2-苯基环己酮 在 palladium on activated charcoal Novozyme 435 immobilized on polyacrylamide 、 ammonium formate 作用下， 以 甲醇 、 水 为溶剂， 反应 43.0h， 生成 (+)-(1S,2R)-2-Phenylcyclohexanamine
  参考文献：
  名称：

  Enantioselective acylation of rac-2-phenylcycloalkanamines catalyzed by lipases

  摘要：

  The kinetic resolution of some 2-phenylcycloalkanamines was performed by means of aminolysis reactions catalyzed by lipases, with Kazlauskas' rule being obeyed in all cases. The size of the ring and the stereochemistry of the stereogenic centers of the amines had a strong influence on both the enantiomeric ratio and the reaction rate of these aminolysis processes. Lipase B from Candida antarctica (CAL-B) showed excellent enantio selectivities toward trans-2-phenylcyclohexanamine in a variety of reaction conditions (E > 150), whereas lipase A from C antarctica (CAL-A) was the best catalyst for the acylation of cis-2-phenylcyclohexanamine (E = 34) and trans-2-phenylcyclopropanamine (E = 9). (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2005.07.033

文献信息

• [EN] ERK INHIBITORS<br/>[FR] INHIBITEURS D'ERK
  申请人：MERCK SHARP & DOHME

  公开号：WO2016100050A1

  公开（公告）日：2016-06-23

  The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

  本发明提供了一种化合物(I)或其药学上可接受的盐、酯和前药，这些化合物是ERK2抑制剂。该发明还提供了一种包括至少一种化合物(I)和药学上可接受的载体的有效量的药物组合物。该发明还提供了一种包括至少一种化合物(I)的有效量和至少一种其他药学活性成分的有效量（例如，化疗药物等）以及药学上可接受的载体的药物组合物。
• METAL CATALYZED DEAROMATIVE 1,2-CARBOAMINATION
  申请人：The Board of Trustees of the University of Illinois

  公开号：US20180362513A1

  公开（公告）日：2018-12-20

  Described herein is the development of an arenophile-mediated, nickel-catalyzed dearomative trans-1,2-carboamination protocol. A range of readily available aromatic compounds was converted to the corresponding dienes using Grignard reagents as nucleophiles. This strategy provided products with exclusive trans-selectivity and high enantioselectivity was observed in case of benzene and naphthalene. The utility of this methodology was showcased by controlled and stereoselective preparation of small, functionalized molecules. A concise synthesis of (+)-pancratistatin and (+)-7-deoxypancratistatin from benzene using an enantioselective, dearomative carboamination strategy has been achieved. This approach, in combination with the judicious choice of subsequent olefin-type difunctionalization reactions, permits rapid and controlled access to a hexasubstituted core. Finally, minimal use of intermediary steps as well as direct, late stage C-7 hydroxylation provides both natural products in six and seven operations.

  本文描述了一个以砂土为介质、镍催化的亲芳香性转位1,2-碳胺化协议的开发。利用格氏试剂作为亲核试剂，将一系列易得的芳香化合物转化为相应的二烯烃。该策略提供了具有独特的反式选择性的产物，并观察到苯和萘的高对映选择性。这种方法的实用性通过对小型、官能化分子的控制和立体选择性制备得到展示。 利用一个具有对映选择性的、亲芳香性碳胺化策略，从苯中简洁合成了(+)-pancratistatin和(+)-7-deoxypancratistatin。这种方法与后续烯烃型双官能化反应的谨慎选择相结合，可以快速、有控制地获得一个六取代核心。最后，最小化中间步骤的使用以及直接的、后期的C-7羟基化反应，使得这两种天然产物可以在六到七个步骤内合成。
• Nickel-Catalyzed Dearomative <i>trans</i>-1,2-Carboamination
  作者：Lucas W. Hernandez、Ulrich Klöckner、Jola Pospech、Lilian Hauss、David Sarlah

  DOI：10.1021/jacs.8b01726

  日期：2018.4.4

  We describe the development of an arenophile-mediated, nickel-catalyzed dearomative trans-1,2-carboamination protocol. A range of readily available aromatic compounds was converted to the corresponding dienes using Grignard reagents as nucleophiles. This strategy provided products with exclusive trans-selectivity and high enantioselectivity was observed in case of benzene and naphthalene. The utility

  我们描述了亲盐介导的、镍催化的脱芳基 trans-1,2-carboamination 协议的发展。使用格氏试剂作为亲核试剂将一系列容易获得的芳族化合物转化为相应的二烯。在苯和萘的情况下，该策略提供了具有独家反式选择性和高对映选择性的产品。通过可控和立体选择性地制备功能化的小分子，展示了这种方法的实用性。
• THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS
  申请人：Biju J. Purakkattle

  公开号：US20080090823A1

  公开（公告）日：2008-04-17

  Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

  本发明涉及的是一种新型的化合物，其结构式如下：其中包括Substituent A和Substituent B，其药学上可接受的盐和溶剂化合物。Substituent A的基团包括杂环芳基、芳基、杂环烷基、环烷基、炔基、烯基、氨基烷基、烷基或氨基。Substituent B的基团包括芳基和杂环芳基。本发明还涉及一种治疗趋化因子介导疾病的方法，例如癌症、血管生成、眼部血管生成性疾病、肺部疾病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和缺血再灌注损伤、疼痛（例如急性疼痛、急性和慢性炎症性疼痛和神经病理性疼痛），使用化合物IA的方法。
• Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
  申请人：Taveras G. Arthur

  公开号：US20070264230A1

  公开（公告）日：2007-11-15

  Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.

  揭示了具有以下结构的新化合物：以及其药物可接受的盐和溶剂化物。包括取代基A的基团的例子包括杂环芳基，芳基，杂环烷基，环烷基，炔基，烯基，氨基烷基，烷基或氨基。包括取代基B的基团的例子包括芳基和杂环芳基。此外，还揭示了使用式IA的化合物治疗趋化因子介导的疾病的方法，例如，癌症，血管生成，血管生成性眼部疾病，肺部疾病，多发性硬化症，类风湿性关节炎，骨关节炎，中风和心脏再灌注损伤，急性疼痛，急性和慢性炎症性疼痛以及神经病理性疼痛。